Objectives of this study were to measure the prevalence of a difference in blood pressure (BP) between arms and determine whether a difference is associated with increased risk of cardiovascular events or death. A prospective cohort study of 247 patients with hypertension was undertaken in one rural general practice in England. The main outcome measures were mean difference in BP between arms and new episodes of myocardial infarction, cerebrovascular event, onset of angina or peripheral vascular disease or death. A total of 57/247 (23%) patients had a mean difference in systolic BP between arms of X10 mm Hg and 8/247 (3%) had a mean difference of X20 mm Hg. A total of 15/247 (6%) patients had a mean difference in diastolic BP between arms of X10 mm Hg. Survival analysis after 4.7 years (range 3.3-5.9) showed a shorter mean survival time without event or death for patients with a difference in systolic BP of X10 mm Hg compared with a difference of o10 mm Hg (3.7 (95% confidence interval, 3.2-4.2) versus 4.8 (4.6-5.1) years; Po0.001; hazard ratio 2.5 (1.5-4.2), P ¼ 0.001). Difference in systolic BP of X10 mm Hg between arms is common in this primary care population and is associated with a shorter survival time to death or new cardiovascular event. Detection of a difference between arms may identify hypertensive patients at increased risk of cardiovascular events. Such an approach would allow more effective targeting of resources in primary prevention strategies.
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Introduction
Measurement of blood pressure (BP) is the investigation most frequently undertaken in primary care, and patients often have different BPs in their arms. This phenomenon, the 'interarm difference' (IAD), was first recognised more than 100 years ago.
1,2 A review of published series reported prevalences of the IAD ranging from 12.0 to 18.4% for a systolic difference (sIAD) X20 mm Hg and from 13.0 to 33.7% for a diastolic difference (dIAD) X10 mm Hg in various populations; 3 for studies without evidence of selection bias or other significant flaws in methods, weighted mean prevalence of a sIAD X10 mm Hg is 19.6% (95% confidence interval, 18.0-21.2%), sIAD X20 mm Hg is 4.2% (3.4-5.1%) and dIAD X10 mm Hg is 8.1% (6.9-9.2%) among patients drawn from the general population. 4 Current guidelines for the management of hypertension do not recognise these prevalences and refer only to checking for an IAD in the initial assessment of patients. 5, 6 Appreciation of the presence of an IAD clearly is vital for the accurate diagnosis and consistent management of hypertension. After a previous small study of a mixed normotensive and hypertensive cohort of patients in primary care, we proposed that the IAD may be caused by peripheral vascular disease. 7 As peripheral vascular disease itself is a strong predictor of cardiovascular disease, [8] [9] [10] [11] [12] we suggested that the IAD also may have prognostic value as a marker for predicting cardiovascular events. This new study was designed to estimate the prevalence of the IAD in a cohort of patients with hypertension from primary care and to test our hypothesis that the IAD may predict an increased cardiovascular risk by examining the effect of the presence of an IAD on event free survival.
Methods

Participants
The Mid Devon Medical Practice consists of three separate surgeries in a rural area. This study was conducted in the main surgery. Participants were patients registered with the author (CEC) in that surgery (two doctors, list size 1900), who had been diagnosed with hypertension in accordance with the current guidelines of the British Hypertension Society 5 and were receiving antihypertensive treatment and being followed up at the start of the study. Patients were excluded if they had only one arm, had previous significant injury, surgery, or paralysis of one arm, or were unable to attend regular review at the surgery.
Measurements
All measurements of BP were taken by one investigator (CEC) using a standard mercury sphygmomanometer (A.C. Cossor & Son (Surgical) Ltd, Accoson Works, London, UK) that was calibrated every 6 months. Standard or large BP cuffs were used as appropriate to the size of each patient's arms. Pairs of BP readings were collected sequentially after the patient had been seated for 5 min; measurement was taken in the arm first presented by the subject and the cuff was then swapped immediately to the other arm and another measurement made. The arm was supported during each measurement. From 2000, single pairs of measurements were obtained opportunistically at the first and subsequent two visits. Return visits were planned every 6 months if BP was controlled or at shorter intervals if treatment for high BP was being adjusted. The three pairs of readings were averaged to obtain a mean systolic and diastolic BP for each arm, which allowed calculation of the mean IAD. Patient characteristics, data on risk factors and previous medical history were recorded at the first visit (Box 1); where no results existed, investigations were ordered. Framingham risk scores were calculated at entry using pretreatment levels. Data on events were collected prospectively for 5 years; events were defined as death, myocardial infarction, cerebrovascular events or a new diagnosis of angina or peripheral vascular disease confirmed in secondary care. Subjects lost to follow up were also noted.
Data analysis
Anonymised data were stored on an Excel spreadsheet and analysed using SPSS for Windows (version 11.5). Scores for the risk of coronary heart disease at 10 years were calculated from the Framingham equation 13 and left ventricular hypertrophy was diagnosed with electrocardiograms using the Perugia scoring system.
14 Patient characteristics and associations of measured IAD with recognised cardiovascular risk factors were compared with t or w 2 tests as appropriate. Entry to the cohort and survival analysis was timed from the second set of readings. Survival was studied with a sensitivity analysis for predefined levels of systolic and diastolic IAD, and Kaplan-Meier survival plots, log-rank statistics and Cox's hazard ratios were calculated as appropriate to the data. A Cox regression model was tested to explore additional effect of the IAD relative to the Framingham score in modelling the survival curves.
Results
Initially, 273 patients (14.3% of the practice's list) were identified as eligible for inclusion in the study and 247 (90%) were recruited by June 2002. At entry, 57/247 (23%) patients had a mean sIAD X10 mm Hg and 8/247 (3%) X20 mm Hg; 15/247 (6%) patients had a dIAD X10 mm Hg. The overall mean difference was 1.6 mm Hg (0.4-2.9) systolic higher on the right and 1.4 mm Hg (0.8-2.0) diastolic higher on the left. There were significant correlations between each individual set of sIAD (Po0.01) and dIAD (Po0.05) measurements.
A sensitivity analysis of predefined levels of sIAD X10, 12, 15, 17 and 20 mm Hg and dIAD X5, 7 and 10 mm Hg was examined for differences in eventfree survival. All levels of sIAD except X20 mm Hg, but none of the dIAD values, showed significantly higher rates of event or death associated with the IAD (Table 1) .
No differences in patients' characteristics at entry were seen for patients with or without a sIAD X10 mm Hg (Table 2 ). No significant difference was seen in the prevalence of pre-existing ischaemic heart disease, cerebrovascular disease or peripheral vascular disease, but a composite history of peripheral vascular disease (PVD), cerebrovascular event (CVE) or ischaemic heart disease (IHD) at Table 3) .
During the study period, 37 IHD events and 13 CVEs occurred in 49 patients. Twenty-six patients died and a total of 60 (24%) patients had an event (Figure 2 ). An association between sIAD X10 mm Hg and reduced eventfree survival (3.7 (3.2-4.2) versus 5.0 (4.8-5.3) years; P ¼ 0.0001; hazard ratio 2.8 (1.9-3.7), Po0.001) remained even after restricting survival analysis to those without any previous history (n ¼ 196).
Discussion
This study confirmed that the IAD is a common finding in a population of patients with hypertension in primary care. It provides evidence for an association between the presence of a sIAD and reduced event-free survival. Although our prevalence figures of 23% with a sIAD X10 mm Hg and 6% with a dIAD X10 mm Hg are lower than the figures that we and others have reported previously from primary care, 3, 7, 15, 16 they are close to the best estimates we have calculated from the most methodologically robust studies. 4 We had anticipated a higher prevalence of the IAD than we reported previously, as it has been shown to occur more frequently in hypertensive than normotensive populations in selective studies, 4, [17] [18] [19] but no previous series of hypertensive patients reported from primary care was available to support this contention. The final prevalence figures were lower than those in our interim report 3 on this cohort, but we have previously shown that prevalence will fall with repeated pairs of measurements. 7 One investigator (CEC) gathered all of the data. However, as events were recorded prospectively, we do not believe that the lack of blinding of the investigator to the IAD would have biased the survival outcomes reported. The sequential method of BP recording was chosen as a pragmatic method of investigation within the consultation; we have addressed the limitations of this method elsewhere. 4 However, the small difference in the magnitude of the absolute BPs between the right and left arms suggests that no systematic bias was introduced by this method, and this is in keeping with data from previously reported large series. 7, [20] [21] [22] Although there was good correlation of IADs between attendances, this study did not measure changes to the IAD over the follow-up period. Therefore, the impact of medication and risk factor modification on the IAD cannot be assessed.
This study was conducted in only one surgery. The practice population distribution showed a trend to older age than the national average with 30% age over 65 compared with 21% from the Health survey for England. 23 However, hypertension is predominantly a condition of older age, and the reported prevalence of patients with hypertension on treatment in this study was 14.3% of the list, which is comparable to 13.7% for women and 11.7% for men reported by the survey. 23 We do not see any reason, therefore, to suggest that our study findings could not be extrapolated to other similar cohorts of patients with hypertension, who are treated in primary care, although the absence of ethnic minority representation in this study may limit its validity for some populations.
From our finding that 23% of patients had a sIAD X10 mm Hg, we estimate that half of the time, or in 11.5% of consultations for BP measurements, the systolic BP of a patient with hypertension could be underestimated by X10 mm Hg if the presence of a sIAD is not specifically excluded. As a reduction in BP of this magnitude has been estimated to prevent 44000 fatal and non-fatal coronary events and 46000 fatal and non-fatal strokes each year in England, 24 the risks of missing the presence of a sIAD are evident and should be emphasised better in current guidelines. 5 This study also showed that a sIAD X10 mm Hg is associated with a reduced survival time to death or new cardiovascular event in a population with hypertension in primary care. It confirms our previous results from a mixed population with normotension and hypertension 7 in a new and larger sample only of patients with hypertension and suggests that detection of a sIAD may identify patients at increased risk of cardiovascular events. The association was present for all predetermined cut-off values of a sIAD apart from X20 mm Hg, although only eight patients had such a high IAD, making analysis of this cut-off unreliable. The association of an IAD with reduced survival was supported by the regression analysis. This study was not powered to model more than two variables; therefore, the Framingham risk score was chosen to model with the sIAD both as a composite measure of likely confounding variables and because it was the predominantly used cardiovascular risk assessment tool at the time the study began. Although there was a non-significant trend to higher age and systolic BP for subjects with a sIAD X10 mm Hg, we did not identify any confounding variables to account for our result. We propose therefore that recognition of a sIAD may provide a pragmatic indicator of the presence of asymptomatic or previously unrecognised peripheral vascular disease in the consulting room and indicate an increased risk of subsequent cardiovascular disease. 3 It is unclear as to why the sIAD was less prevalent in patients with pre-existing ischaemic disease, cerebrovascular event or peripheral vascular disease than those without. No condition on its own was associated significantly with the IAD, there were no confounding differences in variables between the groups at entry and exclusion of subjects with a history of IHD or PVD at entry did not reduce the association of a sIAD with reduced event-free survival. The use of a composite history of ischaemic heart disease, cerebrovascular event or peripheral vascular disease, which assumes a shared pathology, may have been inappropriate and arisen from a sample size effect. Alternatively, the sIAD may represent a marker of early rather than extensive vascular disease, which implies that its potential use is greatest as a predictor of first events. Evidence that peripheral vascular disease first develops proximally in the aorta and its branches may support this idea, 25 and it may be that PVD is more often widely and bilaterally distributed, effectively reducing the measured IAD by the time IHD or PVD has been diagnosed. If this association of reduced survival with a sIAD can be confirmed, detection of an IAD would allow more effective targeting of finite resources for intensive primary prevention strategies, as demanded by the national service framework for coronary heart disease. 26 Our findings need to be confirmed in larger controlled studies, which use a simultaneous method of measurement in more than one centre, and to be correlated with other validated measures of peripheral vascular disease such as the ankle brachial pressure index or specialised imaging or pulse-wave analysis techniques. From the prevalence and survival data reported here, however, we conclude that the IAD should be excluded in all patients with new hypertension for the purposes of accurate diagnosis, clinical assessment and management, and that when a sIAD X10 mm Hg is discovered, aggressive management of risk factors for cardiovascular disease may be warranted. and a grant from Mid Devon Primary Care Research Group. CEC conceived the study, collected, and analysed the data and wrote the manuscript. JLC advised on data analysis and interpretation and wrote the manuscript. RJP advised on data analysis and gave statistical advice throughout. CEC will act as guarantor for this paper. North and East Devon Research Ethics Committee approved the study.
